Form 4 for BSX Boston Scientific
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-01 · accession 0001225208-25-000208 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-03 | 2025-01-02+ | BSX | Sorenson John Bradley | EVP, Gbl Ops | S - Sale+OE | $89.96 | -6,461 | 35.3K | -15% | -$581.2K |
| D | 2025-01-03 | 2025-01-01 | BSX | Sorenson John Bradley | EVP, Gbl Ops | F - Tax | $89.32 | -2,127 | 39.4K | -5% | -$190.0K |
| D | 2025-01-03 | 2025-01-01 | BSX | Sorenson John Bradley | EVP, Gbl Ops | M - OptEx | $0.00 | +4,469 | 41.6K | +12% | $0 |
| D | 2025-01-03 | 2025-01-01 | BSX | Sorenson John Bradley | EVP, Gbl Ops | M - OptEx | $0.00 | -4,469 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-03 | S | D | 2,342 | $89.86 | 32,977 | D | — | — | (F3) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2025-01-01 | F | D | 2,127 | $89.32 | 39,438 | D | — | — | |
| 3 | Common | Common Stock | 2025-01-01 | M | A | 4,469 | $0.00 | 41,565 | D | — | — | (F1) On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. |
| 4 | Common | Common Stock | 2025-01-02 | S | D | 4,119 | $90.02 | 35,319 | D | — | — | |
| 5 | Derivative | Performance Share Units | 2025-01-01 | M | D | 4,469 | $0.00 | 0 | D | — · 2024-12-31 to 2024-12-31 | 4,469 Common Stock | (F1) On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. (F4) Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. |